icon-folder.gif   Conference Reports for NATAP  
 
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
 
 
 
ACH-3102, A Second Generation NS5A Inhibitor, Demonstrates Potent Antiviral Activity in Patients with Genotype 1A HCV Infection Despite the Presence of Baseline NS5A-Resistant Variants
 
 
  Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
 
A. Muir1, J. Hill2, E. Lawitz3, T. Marbury4, L. Robarge5, H. Robison5, J. Hui5, M. Huang5, A. Agarwal5, A. Perelson6, M. Deshpande5, H. Kocinsky5 1Duke Clinical Research Institute, Durham, NC; 2Avail Clinical Research, LLC, DeLand, FL; 3Alamo Medical Research, San Antonio, TX; 4Orlando, FL; 5Achillion Pharmaceuticals, Inc., New Haven, CT, 6Los Alamos National Laboratory, Los Alamos, NM
 
EASL/2012: PRECLINICAL CHARACTERISTICS OF ACH-3102: A NOVEL HCV NS5A INHIBITOR WITH IMPROVED POTENCY AGAINST GENOTYPE-1A VIRUS AND VARIANTS RESISTANT TO 1ST GENERATION NS5A INHIBITORS
http://www.natap.org/2012/EASL/EASL_79.htm

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif

EASL11.gif